Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...

Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

Research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for Gilead Sciences in a report ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...

Gilead Sciences's GILD short percent of float has fallen 8.91% since its last report. The company recently reported that it ...